(Reuters) – The following is a summary of some of the most recent clinical studies on the new coronavirus and efforts to remedy and vaccines that oppose COVID-19, the disease caused by the virus.
More attacks on young adult centers than severe COVID-19
Of the COVID-19 patients treated at 419 U. S. hospitals from April to June, only about 5% were elderly ages 18 to 34. But that organization had “substantial rates of adverse end results,” according to a report published Wednesday in JAMA Internal Medicine. About one in five required intensive care, one in 10 required mechanical ventilation, and nearly 3% died. Although the death rate is lower than that of older adults, it is roughly twice the death rate of young adults from attacks at the center, according to the authors. Obesity, high blood pressure, and diabetes were associated with a higher threat of adverse events. For young adults with more than one of these conditions, the threat of a poor end result similar to that of middle-aged adults without the threat factors. More than a portion of the hospitalized young adults were black or Hispanic, “consistent with previous findings about the disproportionate severity of illness in those demographics,” the authors said. “Given the sharp increase in COVID-19 infection rates among young adults, these effects underscore the importance of infection prevention measures in this aging organization,” the conclusion concluded. (https://bit. ly/2DHodce, https://bit. ly/3bEsJF8)
Antibiotic fails in patients hospitalized by COVID-19
Azithromycin, an antibiotic, does not appear to have advantages in patients hospitalized with COVID-19 who had breathing difficulties, according to a study in Brazil. In 57 hospitals, 243 patients with COVID-19 who needed oxygen or mechanical ventilation were randomly assigned to receive azithromycin, while 183 similar patients did not obtain the antibiotic, all gained some other popular remedy, which in Brazil included hydrochloroquine , an antimalarial drug that other studies have shown to provide little or no advantage, although azithromycin does not appear to have adverse effects. , after 15 days has not been linked to any improvement in patients and has not reduced their death threat. In an April survey of more than 6,000 physicians in 30 countries, azithromycin was the maximum remedy commonly prescribed for COVID-19, the researchers wrote in the medical journal The Lancet. The lack of advantages in this new study “suggests that the systematic use of this strategy and deserve to be avoided,” they said. (https://bit. ly/35l8QBN, https://bit. ly/2ZDBBWT)
The threat of COVID-19 hospitalization may be low
Of nearly 8,500 patients admitted to a giant Boston hospital between early March and May, only two became ill with coronavirus infections that could have been contracted while in the hospital, the doctors report. One of them was probably inflamed by a wife who looked good at daily visits at first, but symptoms evolved while the patient was still hospitalized. This was before the implementation of the guest restrictions and universal masking rules. The other patient developed symptoms 4 days after leaving the hospital. The source of the infection is unknown. According to an article published on JAMA Network Open Wednesday, infection efforts at the hospital included COVID-19 teams compromised with airborne infection isolation rooms, non-public protective devices for staff, and surveillance to make sure they are they will use correctly, universal masking, restriction of guests. and generous testing for COVID-19 in symptomatic and asymptomatic patients. These “robust and rigorous infection practices could possibly be related to a minimized risk” of the spread of COVID-19 in hospitals, the authors conclude. Their results, if replicated in other US hospitals, “should reassure patients,” they said. (https://bit. ly/32bgWLm)
Long-term COVID-19 lung pain possibly over time
COVID-19 lung pain persists long-term but has a tendency to improve, researchers reported at the International Virtual Congress of the European Respiratory Society on Monday. The researchers studied 86 hospitalized COVID-19 patients, 48% of whom had a history of smoking and 21% of whom required intensive care. At 6 weeks after discharge, 47% of patients still reported feeling short of breath. In 12 weeks, that percentage fell to 39%. CT scans still showed lung damage in 88% of patients at six weeks, falling to 56% at 12 weeks. “Overall, this exam shows that COVID-19 survivors have persistent lung failure weeks after recovery. However, over time, a moderate improvement is detected, ”said lead researcher Dr Sabina Sahanic, from the University Clinic of Internal Medicine in Innsbruck, Austria, at a news conference. A similar review presented at the assembly highlighted the importance of early pulmonary rehabilitation after COVID-19 patients are discharged from a ventilator. This comes with balance and gait, muscle building, breathing exercises, and strength training. “The faster rehabilitation began and the longer it lasted, the faster and greater the improvement in walking and breathing talent and muscle gain in patients,” said co-author Yara Al Chikhanie, from the Université Grenoble Alps in France. , in a press release. (https://bit. ly/3bI8uq8)
Open https://tmsnrt. rs/3a5EyDh in an external browser to view a Reuters graph of vaccines and developing.
(Report via Nancy Lapid; Edited through Bill Berkrot)
Subscribe
Sign up for our news explosion.